Hansoh Pharmaceutical’s Ameile Wins Fifth NMPA Indication for EGFR‑Mutated NSCLC
Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that its core product, Ameile (almonertinib), has...
Company
Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D
Eisai (TYO: 4523) China and Xuanwu Hospital of Capital Medical University officially signed a Strategic...
Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy
Beijing Imunopharm Technology Co., Ltd. announced that its independently developed CD19‑targeted CAR‑T cell therapy, IM19,...
InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform
InduPro announced a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly (NYSE:...
MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal
MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY)...
Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity
Shanghai MicuRx Pharmaceutical Co., Ltd (SHA: 688373) announced that the patent for its core product,...
Lilly’s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis
Eli Lilly (NYSE: LLY) announced positive topline results from the TOGETHER‑PsA open‑label Phase 3b trial evaluating...
Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation
Betta Pharmaceuticals Co., Ltd. (SHE: 300558) and Westlake University announced a strategic partnership to advance...
Viva Biotech and CMS Forge AI-Powered Drug Development Alliance
Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8)...
Hisun and ECNU Forge AI Drug Discovery Partnership
Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) and East China Normal University (ECNU) announced a...
Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market
Sciclon Pharmaceuticals (HKG: 6600) forged a collaboration with Zai Lab (NASDAQ: ZLAB, HKG: 9688), securing exclusive promotional rights...
Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that its self-developed Category 1 drug,...
Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal
Pfizer Inc. (NYSE: PFE) and Cartography Biosciences, Inc. announced a strategic collaboration to discover tumor-selective...
Sanofi’s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia
Sanofi (NASDAQ: SNY) announced that Redemplo (plozasiran sodium injection), the world’s first small interfering RNA...
Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC
Bayer AG (VIE: BAYN) announced that cevatertinib (BAY 2927088) has been granted Breakthrough Therapy Designation (BTD)...
ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement...
HutchMed’s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the Phase 3 registration part of the...
Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront
Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly‑owned subsidiary, Gasherbrum Bio, entered into a...
Sichuan Biokin’s BL-B01D1 ADC Wins Priority Review for ESCC in China
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that iza-bren (izalontamab brengitecan, BL-B01D1), its first‑in‑class...
Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy
Ikarovec, a UK‑based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a...